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ABSTRACT 
Recently, controlled and sustained drug delivery has become the standard in modern Pharmaceutical design and an intensive research have been 
undertaken in achieving much better drug product effectiveness, reliability and safety. This interest has been sparked by the advantages shown by 
in situ forming polymeric delivery systems such as ease of administration and reduced frequency of administration, improved patient compliance 
and comfort. The formation of gels depends on factors like temperature modulation, pH change, presence of ions and ultra violet irradiation, from 
which the drug gets released in a sustained and controlled manner. Various biodegradable polymers that are used for the formulation of in situ gels 
include gellan gum, alginic acid, xyloglucan, pectin, chitosan, poly (DLlactic acid), poly (DL-lactide-co-glycolide) and poly-caprolactone. Mainly in situ 
gels are administered by oral, ocular, rectal, vaginal, injectable and intraperitoneal routes. The in situ gel forming polymeric formulations offer 
several advantages like sustained and prolonged action in comparison to conventional drug delivery systems. From a manufacturing point of view, 
the production of such devices is less complex and thus lowers the investment and manufacturing cost. This comprehensive article contains 
approaches, polymers, anatomy of eyes, factor affecting gels and recent advances of in situ gel.  
Keywords: Biodegradable polymers, controlled release, in situ gels, poly (lactic-co-glycolic acid), sustained release.  
INTRODUCTION 
Ophthalmic drug delivery is one of the most interesting and 
challenging endeavors facing the pharmaceutical scientist. The 
anatomy, physiology and biochemistry of the eye render this organ 
exquisitely impervious to foreign substances. The challenge to the 
formulator is to circumvent the protective barriers of the eye 
without causing permanent tissue damage. The primitive ophthalmic 
solutions, suspensions and ointment dosage forms are clearly no 
longer sufficient to combat some present virulent diseases. Due to 
tear drainage, most of the administered dose passes via the naso-
lacrimal duct into the GI tract, leading to side effects. Rapid 
elimination of the eye drops administered often results in a short 
duration of the therapeutic effect making a frequent dosing regimen 
necessary. Ocular therapy would be significantly improved if the 
precorneal residence time of drugs could be increased. Several new 
preparations have been developed for ophthalmic use, not only to 
prolong the contact time of the vehicle on the ocular surface, but also 
to slow down drug elimination. However, these preparations have 
some disadvantages such as poor compliance, especially by elderly 
people and many patients sometimes lose the device without 
noticing it. From the point of view of patient acceptability, a liquid 
dosage form is preferable. This problem can be overcome by the use 
of polymeric solutions, which change to a gel as a result of exposure 
to the physiological temperature, pH or ionic composition of the 
lacrimal fluid. Such a system can be formulated as a liquid dosage 
form suitable to be administered by instillation into the eye, which 
upon exposure to physiological conditions, changes to the gel phase 
thus increasing the pre-corneal residence time of the delivery 
system and enhancing ocular bioavailability. [46-48] 
Sodium alginate, the sodium salt of alginic acid, is a natural 
hydrophilic polysaccharide containing two types of monomers, β-
Dmannuronic acid (M) and α-L- guluronic acid (G). The polymer 
forms three-dimensional hydrogel matrices and the high G content 
alginate forms a low viscosity, free-flowing liquid at concentrations 
suitable for gel formation in the lacrimal fluid. Sodium Alginate was 
chosen as a vehicle for ophthalmic formulations since it exhibits 
several favorable biological properties such as biodegradability and 
non-toxicity. A prolonged precorneal residence of formulations 
containing alginic acid was looked for, not only based on its ability to 
gel in the eye but also because of its mucoadhesive properties. [49] 
Current research and development strategy focus on development of 
drug delivery system that makes clinically established drugs to their 
therapeutic best rather than search for new drug in the traditional 
hit or miss way. 
 
Ophthalmic products, like most other product in the medical 
armamentarium are currently undergoing a process termed 
optimization. New modes of delivering a drug to the eye are being 
activity explored, ranging from a solid hydrophobic device that is 
inserted into the ophthalmic cul-de-sac, to conventionally applied 
dosage from which due to their formulation characteristic markedly 
increases the drug residence time in the orbit of eye, thus providing 
drug for absorption for prolonged periods are for absorption for 
prolonged periods are reducing the frequency of drug 
administration. [1] 
Poor bioavailability of many drugs from topical ophthalmic 
preparation limits therapeutic drug delivery. Furthermore treatment 
of several posterior segment disorders requiring therapeutic 
intravitreal drug level necessitate repeated injections off drugs due 
to the short residence time of drug in the vitreous cavity. Substantial 
effort has been directed towards the development of ocular and 
intraocular drug delivery of ocular and intraocular drug delivery 
system that would prolong the drug retention allowing the drug to 
remain in the contact with ocular milieu for longer duration and thus 
maximize bioavailability. Beyond the issue of bioavailability, patient 
compliance and dexterity issue for drug installation are other 
important consideration that may impact therapeutic drug delivery.  
Delivery of an optimal drug delivery system for eye is most 
challenging and Complex because the eye is one of the sense organ 
most sensitive to external stimuli. 
Although for ophthalmic formulation the total amount of dose 
instilled into the eye can be determined, major amount of 
formulation is lost. It is known that only a fraction of total applied 
dose is bioavailability to target site within the eye from a simple 
solution type dosage form. Actually corneal permeability of a drug is 
quit law and the reason for an early entry of a drug followed by 
rapid decline of drug concentration in the tear has to do with the 
enormous loss of drug from the front of the eye. [2] 
These processes lead to a typical corneal contact time of about 1 to 2 
min. in human for an instilled solution and ocular bioavailability that 
is commonly less than 10%. 
 Eye can accommodate only 7.0µl of drug and major 
portion of drug is lost I lachrymal secretion and rapid 
nasolacrimal drainage resulting in low ocular 
bioavailability. 
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 Systemic absorption of drug drained through the 
nasolacrimal duct result in some undesirable side effect. 
 To maintain the desired therapeutic level it require 
























Factors attributing to poor bioavailability of an opthalmic formulation  




Fig. 2: Drug elimination pathways from the corneal 
area 
The various ophthalmic drug delivery system has been devised 
which offer some Improvement over a conventional liquid dosage 
form by modifying the pulse entry of drugs. These include:- 
 Suspension 
 Ointments 
 Soluble Polymeric gels 
 Pre soaked soft contact lens 
 Bio erodible ocular inserts  
 Emulsion  
 Diffusional devices (Non-erodible inserts) 
 Osmotic system  
 Ion exchange resins  
 Colloidal system including liposomes 
 Nanoparticles 
 These ocular drug delivery system offer some improvement over 
conventional dosage from but because of blurred vision (ointment) 
and lack of patient compliance (inserts) they have not been 
universally accepted. 
  As a result a good ocular bioavailability following topical delivery of 
drug to eye remains a challenger gets to be satisfactory resolved. 
 One of the primary performance characteristics desired of ocular 
drug delivery System is their ability to be retained at delivery site for 
prolonged period of time. This would result in achieving maximum 
drug bioavailability. [3] 
From the point of view of patient acceptability a liquid dosage from 
that can sustain drug release and remain in contact with cornea of 
eye for extended period of time is ideal. 
If the precorneal residence time of a drug could be improvement 
only modestly say to one or two hours then following things can be 
achieved: 
 Improvement local bioavailability  
 Reduced dose concentration  
 Less total drug 
 Improvement patient acceptability  
 Reduced dosage frequently  
This relatively modest but important improvement can be achieved 
by delivery system based on the concept of IN-SITU GELLING 
SYSTEM. [4] 
Such delivery system consists of  phases transition systems that are 
instilled in a liquid from and shift to the gel or sol phases once in the 
cul-de-sac of the eye. 
THE EYE 
ANATOMY OF EYE 
The human eye is a remarkable organ that is able; distinguish from, 
color and distant and with the aid of brain, translate this information 
into what we refer to as vision.  This complex process require a 
highly developed organ, the with its relatively unique architecture 
and physiologic processes.  Not surprisingly the eye has numerous 
protective mechanisms maintain normal functions, but, at times, 
because of anatomic physiologic abnormalities or to frank pathologic 
condition vision is compromised. 
 
Fig. 3: The Human Eye 
It is important to recognize the pathologic or abnormal process, 
which may be well tolerated elsewhere in the body, can threaten 
vision when they occur in the eye. For example, a modest 
inflammation in most areas, of the body will generally be resolved 
quickly with little, if any after effects. A similar inflammation of the 
cornea can lead vascularization with possible vision impairment. It 
is useful therefore to being an examination of the eye with the 
realization that it is extremely sensitive organ, often requiring prone 
medical treatment for pathologic conditions, and always with 
significant need for optimal drug therapy. 
RELEVANT ANATOMY AND PHYSIOLOGY 
It is convenient to consider the eye as four fluid-fill components: 
  Tear chamber  
 Anterior chamber  
 Posterior chamber  
 Vitreous chamber 
 THE TEAR CHAMBER 
This is the portion of the eye that interface with the outside world. It  
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sometimes to as the precorneal area. At its anterior surface are two 
movable “wind-shield wiper” like tissues, the eyelids, which open to 
the atmosphere. At its posterior surface lie the corner and 
conjunctiva all tissues in this chamber are continually bathed by 
tear. 
The Eyelids: The eyelids are two thin, movable flaps of tissue 
covering the eye, with the upper being the larger and more mobile of 
the two. At the tip of both eyelids are eyelashes that serve in a 
protective fashion to sweep foreign objects and perspiration away 
from the eye. The eyelid is lined on the inside by a layer of tissue. 
The conjunctiva and on the outside by muscle and skins. when the 
lids are opened an almond shaped orifice is created.  This orifice is 
referred to as the palpebral fissure. Contained on the nasal side of 
the palpebral fissure are two small opening, one on each lid, termed 
the puncta. The puncta are initial conduits though which tear 
normally drain away from the eye very important to normal 
movement of tears in the tear chamber as well for drug 
bioavailability of topical instilled drugs, is eyelid closure. Squeezing 
or closing the lid causes tears or drug-containing fluids to leave the 
tear chamber.  There are three distinct types of eyelid: - 
 Blinking 
 Voluntary winking 
 Blepharospasm (or the involuntary rapid closing of    
           the eyelids ) 
Blinking, which occurs in humans at a rate of approximately 15 to 20 
times per minute forces removal of drug away from the eye area, as 
dose forcible closing of the lid ? [5] 
The conjunctiva: The conjunctiva is a loose flap of tissue that can be 
manually pulled away from the globe of the eye because it is 
attached to the anterior surface of the lid at one end and to the 
scleral tissue near the cornea at the other end. 
The sclera: The white portion of the eye, next to the cornea and 
beneath the conjunctiva is referred to as the sclera. This is a dense 
fibrous tissue that is very rigid and vascular. 
The Cornea: The curved transparent window of the eye, the cornea, 
allows light rays to enter the eye and become focused as image on 
the retina to give rise to the to the vision processes ; naturally this 
tissue is very important to adequate vision and must be maintained 
in a healthy state by a variety of bioavailability and physiologic 
process. It is critical to vision that is, the tears, cornea aqueous 
humor, lens and vitreous humor are optically transparent. And 
provide the correct refractive index.. 
 There are three principle layers in the cornea each of which is 
separated from the other by a thin membrane. 
 Epithelium 
 Substantial propria or stroma 
 Endothelium 
The two membranes separating the various layers – are Bowman’s 
membrane, which separate the epithelium and stroma, and; 
Descemet’s membrane which separate the stroma and endothelium.  
Tears: To keep the cornea surface with the correct refractive index 
and in a proper state of health, the surface is continuously bathed 
with tears. Tears are formed from several different sources in the 
precorneal portion of eye with the largest part coming from the 
lachrymal gland located in the upper fornix. A number of accessory 
gland contribute lipid, mucous and other substrate to the tears. 
Under normal circumstance tears to not move by themselves across 
the cornea but must be assisted by blinking. Tears then collect and 
are moved to the drainage apparatus for elimination from eye.  
Purpose of tears 
 Flush the eyes to remove foreign object. 
 Maintain corneal moistness so that an optically clear 
window is present  
 Destroy bacteria and other pathogenic substances 
entering the tear chamber 
 Maintain the correct degree of corneal hydration as 
well as a proper supply of oxygen. 
ANTERIOR CHAMBER 
Immediately at the black of the cornea is the anterior chamber. It is 
bounded anterior by the lens and the iris and contains the 
transparent fluid aqueous humor.  
The Iris: (The iris is a tissue that expands (leading to a constraints 
pupil- miosis) and contracts’ (leading to a dilated pupil-mydriasis), 
when exposed to light and chemicals, thus faltering the size of the 
pupil. Biochemical events in iris muscles, as well as the action of the 
drugs, account for the miosis and mydriasis that are observed. Iris 
tissue is porous and very vascular. 
The ciliary processes: The ciliary body contain muscles which 
change the degree of curvature of the lens surface to accommodate 
light that is, they adjust the refractive capacity of the crystalline lens 
for the varying distance of near vision.  Moreover, the ciliary 
processes contribute to formulation of aqueous humor. 
The lens: The lens, like the cornea must remain optically 
transparent and must have the correct index of refraction for near 
vision it must be more rounded for great refraction or bending of 
light rays. This tissue is very dense and like the cornea is avascular 
so that nutrients must be supplied by the bathing fluid.  Because of a 
very limited oxygen supply to the lens, its principle metabolic 
activity is anaerobic glycoside which accounts for some 86% of 
glucose use. The lens is composed of about 65% water with the 
remainder being protein. The water content of the lens decreases 
with age and the lens becomes less pliable and therefore less 
responsive to the suspensory ligament of the ciliary muscle. This 
leads to impairment of a near vision, that is, presbyopia. 
The aqueous humor: Contained within the anterior chamber 
is crystal clear fluid referred to as aqueous humor. The 
aqueous humor serves two main functions… 
Maintenance of intraocular pressure so that the cornea retains an 
optically useful shape. 
Nourishment of the lens and cornea under normal circumstances 
there is about 0.3 ml of fluid in the anterior chamber and about 
0.057 ml in the chamber aqueous humor is continually formed by an 
active process in the ciliary body and is filtered into the posterior 
chamber fluid in the posterior chamber them travels past the iris 
into the anterior chamber where it mixes with whatever humor is 
already present. Once in the anterior chamber a portion of these 
fluid continually drains away from the eye. 
 
THE POSTERIOR CHAMBER 
 
The posterior chamber is a narrow space between the iris and the 
lens containing aqueous Humor. Communication between anterior 
chamber and the posterior chamber is around the lens.  
THE VITREOUS CHAMBER 
The vitreous chamber contains a transparent, material that keeps 
the eyeball in Its rounded shape. This assures proper form to the 
retinal tissue at the rear of the eyeball. [6] 
Table 1 Anatomical and Physiological Features of Human Eye 
S. No. Factor Human Eye 
1. Tear volume (HC) 7.30 
2. Tear turn over rata (µl/min) .5-2.2 
3. Spontaneous dining rate 6-15 times/min 
4. Nictating membrane Absent 
5. Lachrymal puncta 2 
6. pH of lachrymal fluids 7.3-7.7 
7. Miliosmolarity of tears 305 
8. Corneal thickness (nm) 0.52 
9. Corneal diameter(nm) 0.52 
10. Corneal surface area  (  1.04 
11. Ratio of conjuctival Surface and 
corneal surface 
17 
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12. Aqueous humor volume (me) 0.1-0.25 
13. Aq. humor turnover rate (µl/min) 2-3 
 
CLASSIFICATION OF OCULAR DRUG DELIVERY SYSTEMS 
A multitude of ocular dosage forms are available for delivery of drug 
to the eye. These can be classified on the basis of their physical 
forms as follows 
 Liquids: solutions, suspensions, sol to gel systems, 
Sprays 
 Solids: Ocular inserts, Contact lenses, corneal 
shield, Artificial tear, Filter paper Strips. 
 Semi-solids: Ointments, Gels 
 Miscellaneous: Ocular iontophoresis, Vesicular 
systems,  Mucoadhesive dosage Forms, 
Particulates, Ocular penetration enhancers. 
LIQUID DOSAGE FORMS 
Liquids are the most popular an desired state of dosage forms for the 
eye. This is because the drug absorption is fastest from this state. 
The slow release of the drug from the suspended solid provides 
sustained effect for a short duration of time. 
Solution and Suspensions: Solutions are the pharmaceutical forms 
most widely used to administer drugs that must be active on the eye 
surface or in the eye after passage through the cornea or the 
conjunctiva. The drug in the solution is in the solved state and may 
be immediately active. This form also have disadvantage; the very 
short time the solution stays at the eye surface, its poor 
bioavailability (a major portion i.e. 75% is lost via nasolacrimal 
drainage), the instability of the dissolved drug, and the necessity of 
using preservatives.  A considerable disadvantage of using eye drops 
is the rapid elimination of the solution and their poor bioavailability. 
The retention of a solution in the eye is influenced by viscosity, 
hydrogen ion concentration, the osmolality and the instilled volume.  
Sol to gel system: The concept of producing gel in situ (e.g. in the 
cul-de-sac of the eye) was suggested for the first time in the early 
1980s. It is widely accepted that increasing the viscosity of a drug 
formulation in the precorneal region will leads to an increased 
bioavailability, due to slower drainage from the cornea.  Several 
concepts for the in situ gelling systems have been investigated. 
These systems can be triggered by pH, temperature or by ion 
activation. An anionic polymeric dispersion shows a low viscosity up 
to pH 5.0 and will coacervate in contact with tear fluid due to 
presence of a carbonic buffer system which regulates the pH of tears.  
In situ gelling by a temperature change is produced when the 
temperature of polymeric dispersion raised from 25 to 37%.  Ion 
activation of polymeric dispersion occurred due to the presence of 
cations in the tear fluid.  
Vadnere et al studied a number of pluronic polyols with the aim of 
determining factor which influence the transition temperature of the 
hydrogels. All of the pluronic polyols studied showed endothermic 
enthalpy change for sol-gel process. The presence of sodium 
chloride, potassium chloride and sodium sulphate decreased the 
transition temperature whereas the opposite effect was observed 
with urea, alcohol and sodium dodecylsulfate. The enthalpy of gel 
formation was significantly changed by the added substances that 
entropy plays the major role in the gelation process. Rozier et al 
formulated 0.6% w/v GelriteÒ solution and compared its effect with 
equiviscous hydroxyl ethyl cellulose (HEC) solution on timolol 
bioavailability.  An enhanced drug bioavailability and longer 
retention time was obtained in case of GelriteÒ solution as compared 
to HC solution in the rabbit’s eye. Middleton and Robinson prepared 
sol to gel system with mucoadhesive property to deliver the steroid 
fluorometholone to the eye. The formulation gave better release of 
drug over a long period of time in the rabbit’s eye, as compared to 
conventional eye drops. Lindell and Engstrom studied in-vitro 
release rate was retarded with in-situ gelling polymer GelriteÒ 
compare to non-gelling ethyl hydroxy ethyl cellulose system. Kumar 
et al developed in-situ forming gel for ophthalmic drug delivery 
which increased residence time of drug in the eye.  A solution 
containing 1.5% methyl cellulose and 0.3% carbopol at pH 4.0 and 
25°C was found to be an easily flowing liquid capable of 
administration as drop and showed an increase in viscosity and 
conversion to a gel on changing pH to 7.4 by addition of 0.5 M NaOH. 
Kumar and Himmelstein investigated that in-situ gelling behavior of 
carbopol Solution can be modified by addition of hydroxy propyl 
methyl cellulose. They found that hydroxy propyl methyl cellulose-
polyacrlic acid could be formulated as an eye drop and upon 
instillation into the cul-de-sac of the eye can undergo in-situ 
transition to form gels capable of sustained drug release. [7] 
Lin and sung contributed to the field of ophthalmic in situ gelling 
systems by the development and characterization of a series of 
carbopol and pluronic-based solutions by studying their rheological 
behavior. Gunning et al found that the ion activated in situ gelling 
systems of Gelrite for sezolamide and dorzolamide performed better 
then conventional deliveries. 
Sprays: Although not commonly used, some practitioners use 
mydriatics or cycloplegics alone or in combination in the form eye 
spray. These sprays are used in the eye for dilating or for dilating the 
pupil or for cycloplegic examination. 
SOLID DOSAGE FORMS 
The concept of using solids for eye is based on providing sustained 
release characteristics. 
Ocular inserts: Ocular inserts are solid dosage form and can 
overcome the disadvantage reported with traditional ophthalmic 
systems like aqueous solutions, suspensions and ointments. The 
typical pulse entry type drug release behavior observed with ocular 
aqueous solutions (eye drop), suspensions and ointments is replaced 
by more controlled, sustained and continuous drug delivery system. 
The eye drops provided pulse entry pattern of drug administration 
in the eye which is characterized by transient overdose, relatively 
short period of acceptable dosing, followed by prolonged periods of 
under dosing. The ocular maintain an effective drug concentration in 
the target tissues and yet minimize the number of applications 
consonant with the function of controlled release systems. Limited 
popularity of ocular inserts has been attributed to psychological 
factors, such as reluctance of patients to abandon the traditional 
liquid and semisolid medications, and to occasional therapeutic 
failures (e.g. unnoticed expulsion from the eye, membrane ruptures 
etc.). A number of ocular inserts were prepared utilization different 
techniques to make soluble, erodible, and hydrogel inserts. 
Contact lenses: Contact lenses can absorb water soluble drug when 
soaked in drug solutions. These drug saturated contact lenses are 
placed in the eye for releasing the drug for long period of time. In 
humans, the Bionite lens which was made from hydrophilic polymer 
( 2- hdroxy ethyl methacrylate ) has been shown to produce a 
greater penetration of fluorescein. 
Cornea shield: A non cross-linked homogenized, porcine sclera 
collagen slice is developed by a company {Bio-cor (Bausch and Lomb 
pharmaceuticals)}. Topically applied antibiotics have been used in 
conjunction with the shield to promote healing of corneal ulcers. 
Collagen shield arefabricated with foetal calf skin tissue and 
originally developed as a corneal bandage. These devices, once 
softened by the tear fluid, form a thin pliable film that confirms 
exactly to the corneal surface, and undergoes dissolution up to 10, 
24 or 72 hours. Collages film proved as a promising carrier for 
ophthalmic drug delivery system because of its biological inertness, 
structural stability and good biocompatibility. Gussler et al 
investigation the delivery of trifluoro thymidine (TET) in collagen 
shield and in topically drops in the cornea of normal rabbits and 
corneas with experimental epithelial defects. It was found that 
highest drug concentration were found in the eyes treated with 
shields as compared to the eye drops. 
Artificial tear inserts: A rod shaped pellet of hydroxypropyl 
cellulose without preservative is commercially available (Lacrisert). 
This device is designed as a sustained release artificial tear for the  
treatment of dry eye disorder. It was development by Merck, Sharp 
and Dohme 1981. 
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Filter paper strips: Sodium fluorescein and Rose Bengal dyes are 
commercially available as drug impregnated filter paper strips. 
These dyes are used diagnostically to disclose corneal injuries and  
infection such as herpes simplex, and dry eye disorder. [8] 
SEMI SOLID DOSAGE FORMS 
A wide variety of semi solids vehicles are used for typical ocular 
delivery which falls into two general categories: simple and 
compound bases. Simple bases refer to a single continuous phase. 
These include white petrolatum, lanolin and viscous gels prepared 
from polymers such as PVA, carbopol etc. Compound bases are 
usually of a biphasic type forming either water in oil (w/o) or oil in 
water (o/w) emulsions. A drug in either a simple or compound base 
provide an increase in the duration of action due to reduction in 
dilution by teas, reduction in drainage by way of a sustained release 
effect, and prolonged corneal contact time. The most commonly used 
semisolid preparation is ointments consisting of a solid drug in an 
appropriate vehicle base.  
Semi-solid dosage forms are applied once or twice daily and provide 
sustained effects. The primary purpose of the ophthalmic ointment 
vehicle is to prolong drug contact time with the external ocular 
surface. But they present a disadvantage of causing blurring of vision 
and matting of eyelids. Ophthalmic gels are similar in viscosity and 
clinical usage to ophthalmic ointments. Pilocarpine HS is one of the 
ophthalmic preparations available in gel form and is intended to 
provide sustained action of pilocarpine over a period of 24 hours. 
Semi-solids vehicles were found to prolong the ocular contact time 
many ultimately leads to an enhanced bioavailability. 
MISCELLANEOUS DOSAGE FORMS 
Ocular iontophoresis: Iontophoresis is the process in which direct 
current driers ions into cells or tissues. When Iontophoresis is used 
for drug delivery, ions of importance are charged molecules of drug. 
If the drug molecules carry a positive charge, they are driven into the 
tissues at the anode; if negatively charged, at the cathode. 
Ocular iontophoresis offers a drug delivery system that is fast, 
painful, safe and in most cases, results in the delivery of a high 
concentration of the drug to a specific site.  Increased incidence of 
bacterial keratitis, frequently resulting in corneal scarring, offers a 
clinical condition that may benefit from drug delivery by 
iontophoresis. Iontophoretic application of antibiotic may enhance 
their bactericidal activity and reduce the severity of disease; similar 
application of anti-inflammatory agent could prevent or reduce 
vision threatening side effects. But the role of iontophoresis in 
clinical ophthalmology remains to be identified.  
Vesicular systems: Vesicular systems have been developed to 
provide improvement in ocular contact time; providing sustained 
effect and reducing side effects of the drug(s) entrapped. 
Liposomes: Liposomes are phospholipids-lipid vesicles for targeting 
the drugs to the specific sites in the body. Because of their structural 
versatility they can incorporate any kind of drug substance 
regardless of its solubility. They provide the controlled and selective 
drug delivery and improved bioavailability and their potential in 
ocular drug delivery appears greater for lipophilic than hydrophilic 
compounds. Liposomes are vesicles composed of a lipid membrane 
enclosing compounds. Liposomes offer the advantage of being 
completely biodegradable and relatively nontoxi but are less stable 
than particulate drug delivery systems. Liposomes were found to be 
potential delivery system for administration of a number of drugs to 
the eye. [9] 
in-situ GEL SYSTEM 
HYDROGELS 
Hydrogels are polymers endorsed with the ability to swell in water 
or aqueous solvent induced induce a liquid-gel transition. Currently, 
two group of hydrogels are distinguished (Fig) namely: 
 Performed gels  
 In situ forming gels  
 
PERFORMED GELS 
They can be defined as simple systems sets with do not undergo any 
modify after administrate e.g. Include cellulose, poly vinyl alcohol, 
hyaluronic acid, carbomer. They are also called bioadhesive 
polymers. They are usually macromolecular hydrocolloids with 
numerous hydrophilic groups. These polymers can improve drug 
delivery through optimum contact with absorbing surface in order 
to prolong residence time & reducing dosing frequency.  
 
Fig. 4: Classification of ophthalmic hydro gel 
 
IN SITU FORMING GELS 
In situ forming gels are formulation applied as solution, sols or 
suspension that undergoes gellation after installation due to 
physicochemical changes inherent to the eye. This new concept of 
providing a gel in-situ was suggested for the first time in early 
1980’s. [10] 
Several concepts for in-situ gelling system have been investigated. 
These methods have been employed to cause transition on eye 
surface 
 Change in pH 
 Change in temperature  
 Ion activation  
pH triggered system 
Example – 
 Cellulose acetate phthalate latex. 
 Polyacrylic acid polymers (Carbopol & 
polycarbophils) 
pH Triggered in situ gelling systems, are low viscosity polymer 
dispersed in water which undergoes spontaneous coagulation and 
gelling after instillation in conjuctival cul-de-sac. 
Cellulose acetate phthalate (CAP) an anionic polymer shows a very 
low viscosity up to pH-5 but forms a gel in few seconds when come 
in contact with tear fluid (pH 7.2 to 7.4). This system is however 
characterized by higher polymer concentration (30% CAP) that may 
cause discomfort to the patient. 
Polyacrylic acid based polymers which include carbopol, a cross 
linked polyacrylic acid polymer are very sensitive to pH and shows a 
sol-to-gel transformation on changing pH from 4.0 to7.4. The 
polyacrylic acid polymers are effective in small concentration 
(0.5%). 
Change in temperature 
Example 
 Pluronic  
 Poloxamer F27 
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This system is based on polymers which changes from sol-to-gel at 
the temperature of eye (33 to 34°c). An example of this type of 
polymer is poloxamer F127 which is a polyoxyethylene linked with 
polyoxypropylene units. At room temperature the polyxamer remain 
in solution when solution is instilled into the eye surface. The 
elevated temperature causes the solution to become a gel thereby 
prolonging its contact with ocular surface. 
Ion activation systems 
Example:- Gomme “Gellen” (Gelrite) 
These system show sol to gel transformation in the presence of ions. 
Gelrite, a polysaccharide, low acetyl gellan gum, which forms clear 
gel in the presence of mono or divalent cations (sodium ions in tear). 
Advantage of in-situ gelling systems: 
 Generally more comfortable than insoluble inserts. 
 Less blurred vision as compared to ointment. 
 Increased bioavailability due to 
-Increased precorneal residence time. 
-Decreased nasolacrymal drainage of drug. 
 Chance of undesirable side effects arising due to 
systematic absorption of drug through nasolacrimal duct 
is reduced. 
 Drug effect is prolonged hence frequent instillation of 
drug is not required. 
 The carbomer polymeric gel base itself has been 
successfully to treat moderate to severe cases of dry eye 
such as kerato conjunction sicca (KCS). 
APPLICATION OF in-situ GEL SYATEM 
In Situ Gel Formulation For Gene Delivery: Release and 
Formulation 
The in vitro release of plasmid DNA and salmon sperm DNA from IN 
SITU gel formulation was investigation. Two IN SITU gel systems 
were studied (a) an interpolymeric complex (IPC) of water-soluble 
polymers polymethacrylic acid (PMA) and polyethylene glycol (PEG) 
and (b) a Hydroxypropylmethylcellulose carbopol system (H:C). 
Two-way analysis of variance with replication demonstrates that 
both gel composition and medium pH influence significantly the 
release of plasmid DNA from IN SITU gel formulation. When the 
release of both types of DNA was compared, higher release was 
observed for plasmid DNA compared to genomic salmon sperm DNA. 
Conformational analysis of the released plasmid DNA showed that 
DNA was released without degradation, but with remarkable 
conversion from super coiled (SC) to open circular (OC). In addition, 
the tested IN SITU gel systems demonstrate protection from DNAse I 
degradation. The myotoxicity of the injectable gelling solutions was 
assessed by the cumulative release of creatine kinase (CK) over 120 
min from the isolated rodent extensor longus (EDL) muscle. A higher 
level of cumulative CK was observed for IPC when compared to H:C 
(2:1). These results demonstrate that the IN SITU gelling systems can 
be considered as a valuable injectable controlled-delivery system for 
pDNA in their role to provide protection from DNAse degradation. 
[11] 
in-situ cartilage and bone tissue engineering with mesenchymal 
steam cells in hydro gels 
In recent years, biomaterials have begun to play an increasingly 
important role in developing a more effective therapy for the 
treatment of diseased tissue or organs, like osteoarthritis. Current 
biomaterial design encourages cohesive integration with an implant. 
The interface between a biomaterial and surrounding tissue is 
integral to its functionally and long-term performance, particularly 
with musculoskeletal implants, which has dense cellular matrix and 
Lacks the ability to self-repair, such as cartilage. Tissue engineering 
techniques have developed a minimally invasive strategy to place 
the hydrogel into a defect by macromer injection and prompt IN 
SITU photogelation.  The liquid precursor and rapid solidification 
provide the feasibility for implant-defect steric appropriateness, as 
well as cell encapsulation. With this strategy, goat mesenchymal 
stem cells (gMSC) were introduced into a novel biodegradable 
phosphoester hydrogel and transplanted into the cartilage defect for 
3-dimeensional in vitro cultivation until this substitute begins to 
integrate with the surrounding tissue. The development of the 
hydrogel-cartilage transplantation system will be real-timely and 
non-invasively monitored via nuclear magnetic resonance imaging 
(MRI) and eventually by osteo/chondrogenesis analysis. [12] 
Engineered nanoparticles in cancer therapy 
Intense research has led to a more comprehensive understanding of 
cancer at the genetic, molecular and cellular levels providing an 
avenue for methods of increasing antitumor efficacy of drugs while 
reducing systemic side effects. Nano-particulate technology is of 
particular use in developing a new generation of more effective 
cancer therapies capable of overcoming the many biological, 
biophysical and biomedical barriers that the body stages against a 
standard intervention. Nanoparticles show much promise in cancer 
therapy by selectively gaining access to tumor due to their small size 
and modifiability. Typically, through not exclusively, nanoparticles 
are defined as submicroscopic particles between 1 and 100 nm. 
Nanoparticles are formulated out of a variety of substance and 
engineered to carry an array of substance in a controlled and 
targeted manner. Nanoparticles are prepared to take advantage of 
fundamental cancer morphology and modes of development such as 
rapid proliferation of cells, antigen expression, and leaky tumor 
vasculature. In cancer treatment and detection nanoparticles serves 
many targeted functions in chemotherapy, radiotherapy, 
immunotherapy and anti-angiogenesis. Multifunctional nano-
particles perform many of these tasks simultaneously such as 
targeted delivery of a potent anticancer drug at the same time as an 
imaging material to visualize the effectiveness of the drug utilized 
for treatment follow-up. [13] 
Cell Encapsulation in Mammal Reproduction 
Cell encapsulation is an evolving branch of biotechnology with 
numerous applications including the enhancing of reproductive 
performance humans and other mammal species. Over the last 
twenty years male and female gametes and embryos have been 
encapsulations with or without somatic cells, for different purpose, 
such as semen controlled release, in vitro gametogenesis, embryo 
culture after in vitro fertilization and cell preservation. The patents 
and papers underline a widespread use of alginate which is a natural 
anionic biocompatible, biodegradable polymer that mimics the 
extracellular matrix or the basal membrane and supports cell 
functions and metabolism. Gamete and embryo encapsulation 
techniques tend to fall into two main groupings: the “classical” three-
step method, and the more recent one-step method. However all of 
these encapsulation techniques are moving towards new, interesting 
applications since they can be easily tailor-made to fit a variety of 
cell lines. [14] 
IN SITU amplification of oestrogen receptor {alpha} mRNA in 
breast cancer cell lines and tumors 
The aim of this work was to develop a direct IN SITU reverse 
transcription polymerase chain reaction (IN SITU RT-PCR) assay for 
the detection of oestrogen receptor {alpha} (ER{alpha}) mRNA on in 
vitro cell lines and breast tumor cell smears. ER {alpha} mRNA 
amplification was performed on MCF-7 (ER {alpha} positive)and 
MDA-MB-231 (ER { alpha } negative)cell lines as well as on 51 
cytological smears of breast tumor samples from patients. The IN 
SITU amplification of mRNA in cell lines and ex vivo breast tumors 
was successful. However, finding equilibrium between optimal cell 
morphology and PCR performance varied with each tumor, leading 
to difficulty in standardization for daily practice. Nonetheless, IN 
SITU RT-PCR is a useful tool for the detection of ER {alpha} mRNA in 
selected cases, both in vitro and ex vivo. [15]  
Hydrogels formulated IN SITU gelation effective for drug 
delivery and wound healing 
The high water content and soft consistency of hydrogels makes 
them similar to natural living tissue with numerous applications 
across the medical field. Under certain conditions it is desirable to 
prepare a hydrogel at the site of use; unfortunately most polymers 
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must be performed due to the extreme reaction conditions, which 
would not be compatible with the environment of use. Kiser and 
Roberts have overcome this problem with the creation of IN SITU 
gelling hydrogels. Two liquid-state prepolymers are mixed together 
under mild aqueous conditions to form a gel at room temperature 
and or body temperature.  
This system is ideal for injectable drug delivery vehicle applications, 
and it is also possible to use this system in the presence of cells to 
make scaffolds for wound healing. [16] 
DRUGS AND POLYMERS FOR in-situ GEL SYSTEM 
POLYMERS 
Carbomer 940 Hydroyproply methylcellulose 
DRUGS 
 Ciprofloxacin  
 Norfloxacin 
CARBOMER 940 
Introduction: Carbomer is high molecular weight polymer of acrylic 
acid cross linked with allyl ether of sucrose. 
Functional category: Suspending and / or viscosity-increasing 
agent, pharmaceutical aid. 
Synonyms 
Carboxypolymethylene; carboxyvinyl polymer; acrylic acid polymer; 
carbopol. 
Empirical formula:- (C₃H₄O₂)X.(-C₃H₅-sucrose)Y 
Molecular weight: Carbomer 940: 4x10⁶ 
Method of manufacture: A synthetic, high molecular weight, cross-
linked polymer of acrylic acid copolymerized with approximately 
0.75-2% w/w of polyalkyl sucrose. The end product contain 56-68% 
carboxylic acid groups. 
Description: A white, fluffy, acidic, hygroscopic powder with a slight 
characteristic odor. 
Specific Graity: 1:4 
Density, Bulk: 5 g/cm³ 
Equilibrim Moisture Content: 8.0% (20°C and 40% RH) 
Viscosity: 20.5-54.5P (0.2% Spindle 4) 
                     305-394 (0.5% Spindle 6) 
(Brookfield, at 20 rpm using neutralized sol at 25°C) 
Stabiliy and stroage conditions: Dry powder forms of carbomer do 
not support the growth of molds and fungi; however, microorganism 
grows well in unpreserved aqueous dispersions. Carbopol gels 
posses good well in stability and do not support bacterial or fungal. 
Certain preservatives, such as benzoic acid, sodium benzoate and 
benzalkonium chloride, cause a decrease viscosity of the dispersion. 
Carbopol should be stored in tight containers. 
Incompatibilities: Carbomer is incompatible with phenol cation 
polymers, strong acid and high concentration of electrolysis, and is 
dissolved by resorcinol. Exposure to light causes oxidation which is 
reflected in decrease in viscosity. 
Safety: The highest dose tolerated on intragastric administrator 
resin equivalent to 125 mg/kg of dry carbopol resin administrator 1-
2.5% solution in rats. Instillation of 1% solution of carbopol 940 
resin does not produce ocular injury and safe for topical use as 
confirmed by human skin patch testing. 
Application: Emulsifying agent, suspending agent, Gelling agent, 
Thickening agent in ointments and creams; tablet binder in 
sustained-release formulations.  
The various grades of Carbomer available are Carbomer 907, 910, 
934 P, 940 and 941. From these Carbomer 940 was selected due to 
various benefits, it offers, such as thickening efficiency, uniform 
performance, temperature stability, excellent shelf life, microbial 
resistance and safety. 





Synonyms: Methylcellulose; methylcellulose propylene glycol ether 
of methylcellulose; methylcellulose propylene glycol ether. 
Chemical names and cas registery number: 
Cellulose, 2-Hydroxypropylmethylether  
Cellulose Hydroxypropylmethylether (9004-65-3) 
Empirical Formula: C₈H₁₅O₆-(C₁₀H₁₈O₆)N-C₈H₁₅O₅ 
molecular weight: Approx-86,000. 
Description: AN odorless, tasteless, white or creamy-white fibrous 
or granular powder. 
Typical Properties 
Apparent Density: 0.25-0.70 g/cm³ 
Browning temperature: 190-200°C (374-392°F) 
Charring temperature: 225-230°C (437-446°F) 
Enzyme resistance: Comparatively enzyme-resistant, providing 
excellent viscosity-stability during long-term storage. 
Gel formation: Undergoes a reversible transformation from sol-to-
sac upon heating and cooling respectively. 
Gel point: 50°C-90°C, depending upon the grade. 
Ionic charge: No ionic charge (i.e., not a polyelectrolyte). Will not 
complex with metallic salts and ionic organic to from insoluble 
precipitates, thus presenting less compatibility problems. 
Ash: 1.5%-3.0%, depending upon the grade. 
Specific gravity: Approximately 1.3.  
Specific activity: Provide some surfactancy in solution. Surface 
tensions: For such solutions range from 42 to 56 dynes per cm. 
(typical surfactant has a surface tension of 3.0 dynes per cm) 
Stability and storage Conditions: Very stable in dry conditions, 
solution are stable at pH to 11.0 . Aqueous solutions are liable to be 
affected by macro-organisms. When used as viscosity-increasing 
agent ophthalmic solutions, an anti-microbial agent, such as 
benzalkonium chloride should be incorporated store in air tight 
container, in a cool place. 
Incompatibilities: Extreme pH conditions: oxidizing materials. 
Safety: Human and animal feeding studies have shown 
hydroxyproply methylcellulose to be safe.  
Table: 2: Research work on ophthalmic drug delivery system 
S.No. Drug Dosage Form Category of Drug Polymers/base References 
1. Pilocarpine Ointment Mitotic agent Petrolatcum bases [17] 
2. Pilocarpine Emulsion Mitotic agent - [18] 
3. Pilocarpine Sol to gel 
System 
 Cellulose acetate Phthalate [19] 
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4. Pilocarpine Hydrogel  Polyacrylic acid 
& poly acrylamide 
[20] 
5. Pilocarpine Gel  Polyacrylic acid [21] 





7. Flurlsiprofen Gels Anti-inflammatory Pluronic F 127 [23] 









Gels Mitotic agent Pluronic F 127 Methyl cellulose Hydroxypropyl 
Methyl cellulose 
[25] 
10. Tropicamide liposome Mydriatic agent Poly carbophil [26] 
Table 3: Conventional and advanced ocular drug 
S. No. Drug Dosage form Polymer/Bases References 
1. Erythromycin Estolate Hydrogel 
Inserts 
Corpolymer of Polyvinyl Pyrrolidione, Vinyl 
acetate, Glycidly Methacrylate Ethyl acrylate 
[27] 





Poloxamer/ Hyaluronic Acid [29] 
4. Timolol Maleate  gelrite [30] 
 
TYPES OF in-situ GEL SYSTEM 
In vitro properties of in situ forming gels for the parentrals:  
The purpose of this research was to  
Formulation a solution of a water – insoluble interpolymeric 
complex (IPC) containing poly (methacrylic acid ) (PMA), 15 kDa,  
and poly Poly ( ethylene glycol ) ( PEG ), 20 kDa, in a biocompatible 
cosolvent system; [31] 
Demonstrate that the IPC solution can transform into a gel, in situ at 
physiological pH; and  
Determine the ability of the gel to entrap, protect, and control the 
release of macromolecular drugs such as proteins and 
oligonucleotides. Tenary phase diagram were prepared to identify 
cosolvant composition containing N-methylpyrrolidone (NMP), 
ethanol, and water that dissolve the IPC. IPC solutions (40, 50 or 
60% w/v) each containing 1 mg of either model proteins, fluorescein 
isothiocyanate (FITC)- insulin and FITC-albumin, or 24-mer 
phosphorothioate oligonucleotides, were placed in container that 
were immersed in buffer, pH 7.4 . Aliquots of the buffer were 
sampled periodically and analysis for the macromolecular content. 
In addition, in vitro bioactivity of another model protein, α-amylase, 
contained in the IPC solution was also determined. The studies 
demonstrated that a cosolvent containing 1:1:2 ratio of 
NMP/ethanol/water was most suitable for dissolving the IPC. 
Concentrate>30% w/v IPC were required to form the gel, however, 
those mixture containing >60% w/v IPC could not be easily injected 
via 18-22 gauge needle. The gel can entrap and control the release of 
the model macromolecules for up to 6 days, in vitro. In addition, the 
gel can maintain the bioactivity of the protein, α-amylase, for 6-days. 
Therefore an IPC gel can entrap, protect, and control the release of 
macromolecular drugs over a period of 6-days, in vitro, and 
therefore can be considered for in vivo investigation. [32]  
Development of dry powder inhalers 
Development of dry powder inhalers involves powder 
recrystallization, formulation, dispersion, delivery and deposition of 
the therapeutic agent different regions of the airways in 
prophylaxis/ treatment/ diagnosis of pulmonary and systematic 
disorder.  
Conventional powder production by crystallization and milling has 
many limitations resulting into development of alternative 
techniques to overcome the problems. In the last decade many 
patents have been filed claiming improvement in aerosol 
performance of dry powder inhalers through the use of  
Incorporation of fines of carrier to particles to occupy active sites on 
the surface and use of hydrophobic carriers to facilitate 
deaggregation through reduced surface energy and particles 
interaction [33] 
Reducing aerodynamic diameters through particle engineering and 
incorporating drug into porous or low particles density, and/or  
Preparing less cohesive and adhesive particle through corrugated 
surfaces, low bulk density, reduced surface energy and particle 
interaction and hydrophobic additives. Moisture within dry powder 
inhaler (DPI) products has also been shown to influence aerosol 
performance via capillary force and electrostatic interaction. [34] 
Innovations in Transdermal Drug Delivery: Formulations and 
Technique 
The transdermal route of drug delivery has attached researches due 
too many biomedical advantage associated with it. However, 
excellent impervious nature of skin is the greatest challenge that has 
to be overcome for successfully delivering drug molecules to the 
systematic circulation by this route. Various formulation approaches 
used to systematically deliver drug molecules include use of 
prodrugs/lipophilic analogs, permeation enhancers, sub saturated 
systems and entrapment into vesicular systems. Further, the 
adhesive mixture, physical systems of the delivery system and 
release liner influence drug release and its permeation across the 
skin. In addition, great strides in designing delivery systems for 
maximizing percutaneous drug permeation without comprising with 
ease of therapy cannot be neglected in improving functionality of 
transdermal drug delivery systems. [35] 
Modified-release solid formulations for colonic delivery 
The transdermal route of drug delivery has attracted researchers 
due to many biomedical advantages associated with it. However, 
excellent impervious nature of skin is the greatest challenge that has 
to be overcome for successfully delivering drug molecules to the 
systematic circulation by this route. Various formulations 
approaches used to systematically deliver drug molecules include 
use of prodrugs/lipophilic analogs, permeation enhancers, sub 
saturated systems and entrapment into vesicular systems. Further, 
the adhesive mixture, physical system of the delivery systems and 
release liner influence drug release and it’s permeation across the 
skin. In addition, great strides in designing delivery systems for 
maximizing percutaneous drug permeation without comparing with 
ease of therapy cannot be neglected in improving functionally of 
transdermal drug delivery systems. [36] 
Modified-Release solid Formulations for Colonic Delivery 
Solid formulation intended for targeted drug release into the lower 
gastrointestinal (GI) tract are beneficial for localized treatment of 
several disease and conditions, mainly inflammatory bowel diseases, 
irritable bowel syndrome and colon cancer. Also, because of their 
inherent potential to delay or avoid systematic drug absorption from 
the small intestine, colonic formulations can be utilized for 
chronotherapy of diseases which are affected by circadian 
biorthythms (e.g., asthma, hypertension and arthritis), and to 
achieve clinically relevant bioavailability of drugs that are poorly  
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absorbed from the upper parts of the GI tract because of their polar 
nature and/or susceptibility to chemical and enzymatic degradation 
in the small intestine (e.g., proteins and peptides). Modified-release 
(MR) formulation technologies both utilize a single or a combination 
of two or more physiological characteristics of the colon, which 
includes pH, micro flora (enterobacteria), and transit time and 
luminal pressure. Accordingly, these technologies may be grouped 
under four distinct classes; pH-controlled (or delayed-release) 
system, time-controlled (or time-dependent) system, microbially-
controlled system, and pressure-controlled systems. Among these, 
formulations that release drugs in response to colonic pH, 
enterobacteria, or both are most common and promising. [37] 
An IN SITU gelling systems for parenteral delivery 
Polymer complexes formed by electrostatic interactions or hydrogen 
bonds between polymer strands can be utilized as a drug delivery 
systems, as its ability to undergo a sol-gel transformation in 
response to changes in temperature, pH, and solvent concentration 
can lead to an in situ forming delivery system. A polymer complex of 
polyacrylic or polymethacrylic acid and polyethylene glycol, 
previously reported to be formed primarily by hydrogen bonds, is 
being investigated as such a system. Stable below pH≥5.7, the 
complex is soluble in water but dissolves in a hydroalcoholic solvent 
to yield a clear viscous solution. Upon injection, the diffusion of 
ethanol from the liquid transforms the system into a gel upon 
contact with physiological conditions. The gel disappears from the 
site with time due to dissociation of the complex. Water-soluble and 
low molecular weight, the dissociated components can be eliminated 
by glomerular filtration. Using a concentration of 50% ethanol as the 
co-solvent, the system can be injected by syringe. Thus, an 
interpolymer complex of polymethacrylic acid and polyethylene 
glycol may be utilized as a parenteral controlled- release drug 
delivery system. [38] 
FUTURE APPLICATIONS 
Time-controlled Pulsatile Delivery System for Bioactive 
Compounds 
In the body under physiological conditions, many vital functions are 
regulated by pulsed or transient release of bioactive substances at a 
specified time and site. Thus, to mimic the function of living systems, 
it is important to develop new drug delivery devices to achieve 
pulsed delivery of a certain amount of a bioactive compound at 
predetermined time intervals. The ability to deliver bioactive 
compounds and/or therapeutic agent to a patient in a pulsatile or 
staggered release profile has been a major goal in drug delivery 
research over the last two decades. The plasma peak is obtained at 
an optimal time by timing drug administration. The number of doses 
per day can be reduced. Based on the relevance of potential 
therapeutic applications, a variety of design strategies have been 
formulated in the pursuit of pulsatile release. Overall, these systems 
can be categorized into reservoir, capsular and osmotic devices. [39] 
A novel in situ gel for sustained drug delivery and targeting: 
The objective of this study was to develop a novel chitosan-glyceryl 
monooleate (GMO) in situ gel system for sustained drug delivery and 
training. The delivery system consisted of 3% (w/v) chitosan and 
3% (w/v) GMO in 0.33 M critric acid. In situ gel was formed at a 
biological pH. In vitro release studies were conducted in Sorensen’s 
phosphate buffer (pH 7.4) and drug were analyzed either by HPLC or 
spectrophotometry. Characterization of the gel included the effect of 
cross- linker, determination of diffusion coefficient and water uptake 
by thermo gravimetric analysis (TGA). Mucoadhesive property of the 
gel was evaluated in vitro using an EZ-Tester. Incorporation of a 
cross-linker (glutaraldehyde) retarded the rate and extent of drug 
with drug-encapsulation microsphere. Drug release from the gel 
followed a matrix diffusion controlled mechanism. Inclusion of GMO 
enhanced the mucoadhesive property of chitosan by three-to 
sevenfold. This novel in situ system can be useful in the sustained 
delivery of drug via oral as well as parenteral routes. [40] 
Sustained ophthalmic delivery of ofloxacin from a pH triggered 
in situ gelling system 
The poor bioavailability and therapeutic response exhibited by 
conventional ophthalmic on solutions due to rapid precorneal 
elimination of the drug may be overcome by the use of in situ gel 
forming systems that instilled as drops into the eye and undergo a 
sol-gel transition in the cul-de-sac. The present work describes the 
formulation and evaluation of an ophthalmic delivery system of an 
antibacterial agent, ofloxacin, based on the concept of triggered in 
situ gelation. Polyacrylic acid (Carbopol (R) 940) was used as the 
gelling agent in combination with hydroxyprpylmethylcelluose 
(Methocal E50LV) which acted as a viscosity enhancing agent. The 
developed formulation was therapeutically efficacious stable, non-
irritant and provided sustained release of the drug over an 8-h 
period. The developed system is thus a viable alternative to 
conventional eye drops. [41] 
SUMMARY 
Current research and development technique are based on the 
development of drugs which can have the following proportion:  
 Better patient compliance 
 Easy administrator  
 More bioavailability  
 Less frequency of dosing  
 Better permeability  
 Immediate results 
Development of an ophthalmic drug delivery system is most 
complex of all because of the fact that eye is the most sensitive to 
outer environment. On the more ocular drugs have less 
bioavailability owing to the fact that eye can accommodate only 7.0 
µl of the drug instilled and the rest is lost with the lachrymal 
secretion. So to obtain required therapeutic effect, it requires 
frequent instillation which is again not considered a good practice 
by the patient. Various drug delivery systems have been the back 
point of blurred vision and lack of patient compliance. An ideal 
ophthalmic drug delivery system should have the property of 
sustaining drug release and remain in contact with the cornea of eye 
for extended period of time. The answer to this entire problem can 
be given by the in situ gelling systems which provide [42] 
 Improved local bioavailability  
 Reduce dose concentration 
 Improvement patient acceptability  
 Reduce dosage frequency 
 In situ gel systems are basically liquid preparation which form 
gel in contact with the cornea in the cul-de-sac of the eye 
 Change in pH 
 Change in temperature 
 Ion activation  
 The aqueous polyacrylic acid solution (carbopol solution) 
containing a viscosity enhancing agent hydroxyl methyl 
cellulose can be used as in-situ gelling ophthalmic delivery 
system. The system offers an effective alternate to system 
based on using carbopol alone. [43] 
 The in-situ gel forming system will have good patient 
acceptance because it is easy to instilled into the eye and 
gradually erodes by dissolution of the gel, obviating the need 
for removal. [44] 
 The long residence time of gel formed in situ along with its 
ability to release drug in a sustained manner will assist in 
enhancing ocular bioavailability. [45] 
 Change in the concentration of the polymers affect the 
rheological behavior and release profile of incorporated drug 
from the gels. This offers flexibility in design of in situ gel 
formulated system with desirable rheological properties and 
drug release rate. [45] 
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